Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin in Hemodialysis Patients With and Without Residual Urine Volume
2021-000733-14Phase 2Active
- Sponsor
- Medical University of Vienna
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cardiac morbidity, end-stage kidney disease (ESKD) and type 2 diabetes mellitus (T2DM) comparing Dapagliflozin with Placebo (2 arms). Primary endpoint: Change in left ventricular mass index. Started Jun 2022; status: active.
02
Drugs
dapagliflozin
03
Conditions
cardiac morbidityend-stage kidney disease (ESKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2021-000733-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000733-14.